(+)-Syringaresinol
Based on 1 publication(s) in Google Scholar
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.78%
- CAS No.: 21453-69-0
- Formule: C22H26O8
- Masse moléculaire:418.44
-
Stockage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (+)-Syringaresinol
More
Activité biologique
IC50: 329.4 μM (NFAT transcription factor)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | ED50 |
13.92 μg/mL
Compound: (+)-syringaresinol
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 1453182] |
| A549 | ED50 |
14.9 μg/mL
Compound: 7
|
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
|
[PMID: 1593281] |
| A549 | IC50 |
>100 μM
Compound: 42
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| A549 | IC50 |
>20 μg/mL
Compound: 13
|
Cytotoxicity against human A549 cells
Cytotoxicity against human A549 cells
|
[PMID: 23511021] |
| B16-BL6 | IC50 |
>100 μM
Compound: 42
|
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| HeLa | IC50 |
>100 μM
Compound: 42
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| Hep 3B2 | IC50 |
15.73 μg/mL
Compound: 13
|
Cytotoxicity against human Hep3B cells
Cytotoxicity against human Hep3B cells
|
[PMID: 23511021] |
| HepG2 | IC50 |
>20 μg/mL
Compound: 13
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 23511021] |
| HT-1080 | IC50 |
>100 μM
Compound: 42
|
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| HT-29 | ED50 |
15.5 μg/mL
Compound: 7
|
Cytotoxicity against human HT-29 cells after 7 days
Cytotoxicity against human HT-29 cells after 7 days
|
[PMID: 1593281] |
| KB | IC50 |
>47.8 μM
Compound: 10
|
Cytotoxicity against human KB cells by sulforhodamine B assay
Cytotoxicity against human KB cells by sulforhodamine B assay
|
[PMID: 26928423] |
| Lewis lung carcinoma cell line | IC50 |
>100 μM
Compound: 42
|
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
|
[PMID: 18440233] |
| MCF7 | ED50 |
30.31 μg/mL
Compound: (+)-syringaresinol
|
Cytotoxicity against human MCF7 cells after 7 days
Cytotoxicity against human MCF7 cells after 7 days
|
[PMID: 1453182] |
| MCF7 | ED50 |
3.69 μg/mL
Compound: 7
|
Cytotoxicity against human MCF7 cells after 7 days
Cytotoxicity against human MCF7 cells after 7 days
|
[PMID: 1593281] |
| MCF7 | IC50 |
>20 μg/mL
Compound: 13
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 23511021] |
| MDA-MB-231 | IC50 |
>20 μg/mL
Compound: 13
|
Cytotoxicity against human MDA-MB-231 cells
Cytotoxicity against human MDA-MB-231 cells
|
[PMID: 23511021] |
| N9 | IC50 |
2.68 μM
Compound: 16
|
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 28073678] |
| P388 | ED50 |
0.56 μg/mL
Compound: (+/-)-Syringaresinol
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 3783168] |
| PANC-1 | IC50 |
61.1 μM
Compound: 6
|
Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay
Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay
|
[PMID: 28495081] |
| RAW264.7 | IC50 |
0.047 mM
Compound: 8
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| RAW264.7 | IC50 |
0.047 μM/mL
Compound: 8
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs
|
[PMID: 18986199] |
| RAW264.7 | IC50 |
14.8 μM
Compound: 15
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method
|
[PMID: 21435874] |
| RAW264.7 | IC50 |
>50 μM
Compound: 6
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 25592708] |
| RAW264.7 | IC50 |
21.6 μM
Compound: 15
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay
|
[PMID: 25666824] |
| RAW264.7 | IC50 |
>50 μM
Compound: 18
|
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay
|
[PMID: 33939429] |
| Vero | IC50 |
>47.8 μM
Compound: 10
|
Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay
Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay
|
[PMID: 26928423] |
(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED50 0.41 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 21453-69-0
-
Appearance Solid
-
Masse moléculaire 418.44
-
Formule C22H26O8
-
Color White to off-white
-
SMILES
OC1=C(C=C(C=C1OC)[C@@H]2[C@@]3([C@]([H])(CO2)[C@H](OC3)C4=CC(OC)=C(C(OC)=C4)O)[H])OC
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Pak J Pharm Sci
Syringaresinol inhibits ferroptosis and ameliorates glucocorticoid-induced MC3T3-E1 osteoporosis by modulating the Nrf2/SLC7A11/GPX4 pathway. [Abstract]2026 Jan;39(1):102-116. PMID: 41482780
Solvant et solubilité
DMSO : 25 mg/mL (59.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (279 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cai XF, et, al. Inhibitory lignans against NFAT transcription factor from Acanthopanax koreanum. Arch Pharm Res. 2004 Jul;27(7):738-41. [Content Brief]
[2]. Badawi MM, et, al. Plant anticancer agents XXVII: Antileukemic and cytotoxic constituents of Dirca occidentalis (Thymelaeaceae). J Pharm Sci. 1983 Nov;72(11):1285-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3898 mL | 11.9491 mL | 23.8983 mL | 59.7457 mL |
| 5 mM | 0.4780 mL | 2.3898 mL | 4.7797 mL | 11.9491 mL | |
| 10 mM | 0.2390 mL | 1.1949 mL | 2.3898 mL | 5.9746 mL | |
| 15 mM | 0.1593 mL | 0.7966 mL | 1.5932 mL | 3.9830 mL | |
| 20 mM | 0.1195 mL | 0.5975 mL | 1.1949 mL | 2.9873 mL | |
| 25 mM | 0.0956 mL | 0.4780 mL | 0.9559 mL | 2.3898 mL | |
| 30 mM | 0.0797 mL | 0.3983 mL | 0.7966 mL | 1.9915 mL | |
| 40 mM | 0.0597 mL | 0.2987 mL | 0.5975 mL | 1.4936 mL | |
| 50 mM | 0.0478 mL | 0.2390 mL | 0.4780 mL | 1.1949 mL |
(+)-Syringaresinol Related Classifications
HY-126030 Related Classifications
Powered by Bioz